A small exploratory study suggests that urine may contain measurable metabolic signals associated with the cause, clinical state and later recovery of people with disorders of consciousness after severe brain injury.
Researchers analysed urine samples from 37 patients with disorders of consciousness using untargeted metabolomics. They found distinct metabolic patterns when patients were grouped by injury cause, level of consciousness and prognosis. Several metabolites also showed strong discrimination between patients with different recovery outcomes.
The findings are preliminary and do not establish a clinical urine test for consciousness or recovery. The cohort was small, the analysis was exploratory and the metabolic signals require validation in larger, independent and longitudinal patient groups. Even so, the study provides evidence that a non-invasive sample may capture aspects of the systemic biology accompanying severe brain injury and recovery.
Why disorders of consciousness are difficult to assess
Disorders of consciousness can follow severe traumatic or non-traumatic brain injury. Patients may remain in an unresponsive wakefulness syndrome or show signs consistent with a minimally conscious state. Clinical assessment is challenging because observable behaviour can fluctuate and because the biological processes supporting recovery are complex.
Recovery requires more than preservation of brain structure. Neuronal repair, synaptic reorganisation and the reactivation of large-scale neural networks are metabolically demanding processes. Long Xu, Qianqian Ge and colleagues investigated whether some of those processes might leave detectable metabolic signatures in urine.
The peer-reviewed study was published in Scientific Reports on 25 September 2026.
How the researchers studied urine metabolites
The study included 37 patients with disorders of consciousness. Urine samples were analysed using untargeted ultra-performance liquid chromatography coupled with mass spectrometry, an approach designed to detect a broad range of small molecules rather than measuring only a predetermined set.
Patients were classified according to three clinically relevant dimensions: the cause of their brain injury, their diagnostic level of consciousness and their subsequent prognosis. The researchers compared traumatic brain injury with non-traumatic brain injury, minimally conscious state with unresponsive wakefulness syndrome, and patients showing different recovery outcomes.
The analytical pipeline included principal component analysis and orthogonal partial least squares discriminant analysis to examine differences in metabolic profiles. Candidate metabolites were selected using statistical criteria including variable importance and fold-change measures, followed by pathway enrichment analysis. Receiver operating characteristic analysis was also used to examine the discriminatory performance of selected metabolites.
Traumatic brain injury showed a distinct metabolic profile
Patients whose disorders of consciousness followed traumatic brain injury showed metabolic differences from those with non-traumatic causes. Pathways involving pyrimidine metabolism, nitrogen metabolism and arginine biosynthesis were elevated in the traumatic brain injury group.
The researchers interpreted these patterns as potentially consistent with sustained oxidative stress and regenerative activity after traumatic injury. Pyrimidines are involved in nucleotide biology, while arginine and nitrogen pathways participate in numerous processes relevant to cellular metabolism and tissue responses.
That interpretation remains mechanistic rather than causal. A urinary metabolite is a peripheral signal influenced by metabolism across the body, and the study did not demonstrate that the measured pathway changes directly caused neuronal repair.
Metabolic patterns also differed by consciousness level
The investigators also identified differences between patients in a minimally conscious state and those classified with unresponsive wakefulness syndrome. The patterns included changes related to ascorbate and aldarate metabolism as well as nitrogen and arginine pathways.
The authors proposed that ascorbate-related and dopaminergic metabolic activity could be relevant to neural responsiveness and recovery. This is an important hypothesis rather than proof that these pathways restore consciousness. Metabolomics can reveal associations and pathway-level clues, but it cannot by itself demonstrate the direction or function of the underlying biological processes.
Recovery was associated with amino acid and tryptophan metabolism
When patients were grouped according to prognosis, those with improved outcomes showed alterations involving amino acid and tryptophan metabolism. The researchers suggested that these patterns may reflect biological processes related to neuroplasticity and neural recovery.
Several individual metabolites emerged as candidate prognostic markers. Dibutyl decanedioate showed particularly strong discriminatory performance within the study cohort. S-lactoyl-glutathione and S-adenosyl-L-homocysteine were among other metabolites associated with outcome differences.
These findings should be interpreted as biomarker discovery rather than clinical validation. Strong performance in a sample of 37 patients can overestimate how well a marker will perform in a new population, particularly when candidate features are identified and evaluated within the same exploratory dataset.
Why urine could be useful
Urine has practical advantages for repeated biological monitoring. Collection is non-invasive, relatively inexpensive and easier to repeat than many imaging or invasive sampling procedures. This could be especially valuable in patients with severe neurological impairment who may require prolonged monitoring.
If robust metabolic markers are eventually validated, urine metabolomics could potentially complement neurological examination and other clinical tools. It might also help researchers track how systemic metabolism changes during recovery and identify biological pathways worth testing in mechanistic studies.
The present study does not support using urinary metabolites to make treatment or prognosis decisions. The work is better understood as an early discovery study that identifies candidate signals for future investigation.
Important limitations
The most important limitation is the sample size. With only 37 patients, subgroup comparisons can involve relatively few observations and are vulnerable to unstable estimates. Larger multicentre cohorts are needed to determine whether the reported metabolic patterns reproduce across different patient populations.
The study also relied on untargeted metabolomics, which is designed for broad discovery. Candidate metabolites and pathways identified through this approach generally require targeted analytical confirmation before they can be considered reliable biomarkers.
Urinary chemistry can be affected by hydration, kidney function, diet, medication and other systemic factors. Severe brain injury patients may also differ in medical treatment and general physiological condition. These influences can complicate attempts to attribute a peripheral metabolic signal specifically to neuronal regeneration.
Finally, the associations do not establish that the identified pathways drive consciousness recovery. Longitudinal sampling, independent validation and targeted mechanistic experiments are necessary to determine whether the signals track recovery over time and whether any have direct biological relevance to neural repair.
What the study adds
The study provides evidence that urinary metabolic profiles can differ across clinically meaningful categories in disorders of consciousness. The patterns were not limited to a single comparison. Differences appeared across injury cause, consciousness level and prognosis, suggesting that peripheral metabolism may reflect multiple dimensions of severe neurological injury.
The results also generate specific hypotheses around pyrimidine, nitrogen, arginine, ascorbate, amino acid and tryptophan metabolism. These pathways can now be examined more directly in larger studies designed to distinguish useful biomarkers from cohort-specific findings.
For patients and clinicians, the key message is not that a urine test can currently predict awakening. Rather, the research shows that a readily obtainable biological sample may contain measurable signals associated with recovery processes. Establishing whether those signals are sufficiently accurate and reproducible for clinical use will require substantially more evidence.
Source Information
Study: Urine metabolomics reveals key pathways supporting neuronal regeneration and consciousness recovery in disorders of consciousness
Authors: Long Xu, Qianqian Ge, Hezhen Lu, Chen He, Hao Li, Xiaoli Geng, Xueling Chen, Xiaoyan Liu, Haidan Sun, Zhengguang Guo, Jiameng Sun, Binbin Zhang, Feng Qi, Jianghong He and Wei Sun
Journal: Scientific Reports
Published: 25 September 2026
DOI: 10.1038/s41598-026-67114-8
Study design: Exploratory observational metabolomics study
Sample: 37 patients with disorders of consciousness
